Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-11-2015 | Award Amount: 6.44M | Year: 2016
The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detect, characterize and monitor neurovascular and cardiovascular disease. Spectral Photon Counting Computed Tomography (SPCCT) is a new imaging modality, currently in development, with a totally new type of detection chain designed to provide high count-rate capabilities while offering energy discrimination with high spatial resolution of 200m. Based on this discrimination, SPCCT can detect and quantify accurately a large variety of atoms (including Gadolinium, Gold, Bismuth) by using the K-edge technique. SPCCT, by a more accurate, less invasive (in comparison with IVUS and coronary angiography) and reliable evaluation of vascular inflammation will allow earlier disease diagnosis such as plaque inflammation before rupture, leading to improved clinical decisions and outcomes. This will be achievable with a high spatial resolution combined to the newly developed vascular inflammation specific contrast agent detected with high quality K-edge technique that can only be provided by a multi-spectral X-ray system. The project will therefore provide a complete tool (acquisition system and specific probes) dedicated to CV imaging. It will finally contribute to: Improved early diagnosis of atherosclerosis, prevention of acute event (MI, stroke) and personalized preventive treatment; Improved management of patient presenting with an acute CV event and clinical validation of treatment efficiency; Sustainability and harmonization of healthcare systems, as costly disorders of heart failure and stroke-related disability would be better prevented and efficiently treated; Economic growth in the EU diagnostics sector, through the development of new targeted contrast materials for SPCCT by SMEs.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-11-2015 | Award Amount: 6.45M | Year: 2016
Cancer is one of the most devastating diseases the world is currently facing, accounting for 7.6 million deaths in 2008 (WHO). Cancer is usually detected through advanced medical imaging. Early detection is very important as it increases the chances of survival and the potential for full recovery. Further, The high level of sophistication in treating cancer has led to a new unsolved problem, the differentiation between treatment effect, regrowth or pseudo-progression of the tumour. Here, we aim to develop and bring to the clinic a potentially disruptive new technology to characterize and image glucose delivery, uptake and metabolism in cancer. Recently we managed to demonstrate the sensitivity of a technique, named glucose-based Chemical Exchange Saturation Transfer (glucoCEST), to detect native (-D-glucose) glucose uptake in tumours. In addition, recent developments have shown glucose analogues, such as 3-oxy-methyl-D-glucose (3OMG) can be used as potential non-metabolisable tracers using the same technique. In this proposal, we aim to bring the combination of native D-glucose and 3-oxy-methyl-D-glucose as a combined examination to the clinic to assess cancer glucose uptake and metabolism, thereby providing a cheap, widely available, more comprehensive, non-invasive alternative to nuclear medicine techniques currently used for cancer assessment within Europe.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.2-2 | Award Amount: 12.84M | Year: 2013
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands. Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners from academia, a European association, SMEs and a large pharmaceutical company. NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development. In NanoAthero, the nanocarriers carrying compounds to visualize thrombus or vulnerable plaques, or to deliver therapeutic agents should be suitable for proof-of-concept in patients. Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma. NanoAthero aims to propose nanosystems for thrombus imaging, stroke treatment and plaque stabilization in high-risk patients. Molecular imaging and therapeutic treatments in NanoAthero are based on feasible approaches.
BRACCO IMAGING S.p.A. | Date: 2016-04-15
The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid form may be obtained by employing water as a solvent, which is a non-toxic solvent, easy to handle and basically not requiring troublesome health or safety precautions.
Bracco Imaging SPA | Date: 2016-01-20
A process for the preparation of (S)-N,N-bis[2-hydroxy-1 (hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (iopamidol) starting from 5-amino-N,N-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-1,3-benzenedicarboxamide (II)a) reacting the compound of formula (II) with a suitable protecting agent, to give a compound of formula (III)_(1) is a hydrogen atom, a C_(1)-C_(4) straight or branched alkyl group or a C_(1)-C_(4) straight or branched alkoxy group, R_(2) is hydrogen, a C_(1)-C_(4) straight or branched alkyl group or a C_(1)-C_(4) straight or branched alkoxy group and R_(3) is a C_(1)-C_(4) straight or branched alkyl group, a trifluoromethyl or a trichloromethyl group;b) acylating the amino group in position 5 of the intermediate compound of formula (III), by reaction with a (S)-2-(acetyloxy)propanoyl chloridewherein R is defined above; andc) removing all the acyl groups present in the compound of formula (IV) under basic conditions, with prior cleavage of the cyclic protections of the hydroxy groups in the carboxamido substituents under acidic conditions, when R is a group of formula A carboxamido hydroxy groups under acidic conditions.
Bracco Imaging S.p.A. | Date: 2016-02-10
A fluid delivery system may include a container that houses a medical fluid, a fluid pressurizing unit, and a fluid transfer set that transfers the medical fluid from the container to the fluid pressurizing unit. To validate the integrity and sterility of the fluid delivery system, the system may undergo testing protocols to evaluate the susceptibility of the system to pathogenic ingress, chemical degradation, and/or fluid cross-contamination between patient fluid delivery procedures. The testing protocols may help ensure that delivery system components used during multiple different fluid delivery procedures perform as well as if the components were replaced after each fluid delivery procedure.
Bracco Imaging S.P.A. | Date: 2014-04-10
The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.
Bracco Imaging S.P.A. | Date: 2014-01-30
The invention relates to a method of Magnetic Resonance (MR) detection, in particular ^(13)C-MR detection, by using a diagnostic medium comprising a hyperpolarized ester, in particular ethyl acetoacetate. The method comprises the detection of the MR signal of a hyperpolarized ^(13)C carboxylic ester and of its respective hyperpolarized metabolite.
Bracco Imaging S.P.A. | Date: 2015-02-16
The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.
Bracco Imaging SPA | Date: 2016-01-27
The present invention relates to a process for the preparation of a solid form of the gadobenate dimeglumine compound that essentially comprises obtaining a solution of the said compound in a suitable solvent A and adding, under stirring and appropriate temperature conditions, the said obtained solution in a suitable organic solvent B, acting as an appropriate antisolvent and favoring the formation and precipitation of solid particles of the complex compound that can be easily collected by filtration in high yields and in a reliable way.